Related Experiment Video
Updated: Jul 13, 2025

07:37
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
2.8K
Somatic structural variation signatures in pediatric brain tumors
1Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, USA.
Cell Reports
|October 18, 2023
Summary
Somatic structural variations (SVs) in pediatric brain tumors show diverse mutational signatures, differing significantly from adult cancers. These genomic alterations play crucial roles in the progression of childhood brain cancers.
Area of Science:
- Genomics
- Pediatric Oncology
- Cancer Biology
Background:
- Brain cancer is the leading cause of cancer-related death in children.
- Somatic structural variations (SVs) are large-scale DNA alterations that are poorly understood in pediatric brain tumors.
Purpose of the Study:
- To detect and characterize somatic structural variations (SVs) in pediatric brain tumors.
- To infer the mutational mechanisms underlying SVs in different pediatric brain tumor types.
- To compare SV signatures in pediatric brain tumors with those in adult cancers.
Main Methods:
- Whole-genome sequencing of 744 pediatric brain tumors from the Pediatric Brain Tumor Atlas.
- Detection of 13,199 high-confidence somatic SVs.
- Decomposition of mutational signatures for clustered complex SVs, non-clustered complex SVs, and simple SVs.
Main Results:
- A high number of somatic SVs were detected with significant diversity across tumor types.
- Distinct SV mutational signatures were identified in various tumor types, suggesting unique genome instability mechanisms.
- Pediatric brain tumor SV signatures differ substantially from those in adult cancers.
- Convergence of SV signatures on major cancer driver genes indicates their role in disease progression.
Conclusions:
- Distinct molecular mechanisms drive genome instability in different pediatric brain tumor types.
- Somatic SVs play vital roles in the progression of pediatric brain tumors.
- Understanding these SVs is critical for developing targeted therapies for childhood brain cancers.

